完成本地首例手术，深圳希玛眼科全面启动ICL(V5)项目

Core Insights - The launch of the EVO+ICL(V5) project at Shenzhen Hima Lin Shun Chao Eye Hospital marks a significant advancement in refractive surgery technology in the Greater Bay Area, allowing local patients access to cutting-edge vision correction techniques [1][2] Group 1: Project Launch and Significance - The Shenzhen Hima Eye Hospital initiated the EVO+ICL(V5) project on January 7, 2023, following the first surgery on January 5, 2023, establishing a clinical application cooperation center and certifying surgeons [1][2] - The project is supported by strategic partnerships with leading global medical manufacturers, emphasizing the importance of international technology sharing for domestic healthcare [2][3] Group 2: Clinical Achievements and Future Plans - Shenzhen Hima Eye Hospital has performed over 10,000 ICL surgeries, showcasing its comprehensive refractive correction system and readiness for the new technology [3] - The hospital aims to implement strict operational standards and quality control systems to ensure the safe and precise application of the EVO+ICL(V5) technology [3] Group 3: Patient Experience and Technology Advantages - The first patient to undergo the EVO+ICL(V5) surgery reported significant improvements in vision quality, achieving a vision score of over 1.0 after the procedure [4] - The V5 technology offers four key advantages: larger optical zone design, improved night vision sensitivity, Swiss precision manufacturing, and over 30 years of clinical validation with more than 3 million implants globally [4]